As per Global Insight services’ assessment, about 170+ prominent pharma and biotech giants are working on 170+ drugs in the Asthma – pipeline landscape globally. Asthma Pipeline Insight, 2023” report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies : https://www.globalinsightservices.com/request-sample/GIS31206
Asthma is a chronic inflammatory disease of the lungs. The airways in the lungs become narrow due to inflammation and tightening of the muscles around the small airways and also due to excess mucus. It is characterized by airflow obstruction and triggers bronchospasms.
Signs and symptoms of asthma includes shortness of breath, chest tightness, recurrent episodes of wheezing and cough. These symptoms vary from person to person. The symptoms get worse during night or with exercise.
Report Highlights
Global Insight Service’s, Asthma – Drug Pipeline Landscape, 2023 report provides an overview of the Asthma pipeline drugs. This report covers detailed insights on Asthma drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Asthma pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Key Players
- 3SBio Inc
- 4D Pharma Plc
- AazeinTx Inc
- AB Science SA
- Adial Pharmaceuticals Inc
- Advagene Biopharma Co Ltd
- Aeon Respire Inc
- Akari Therapeutics Plc
- Aldeyra Therapeutics Inc
- Algomedix Inc
- ALK-Abello AS
- Allakos Inc
- Allergy Therapeutics Plc
- Alveolus Bio Inc
- Alvotech SA
- Amgen Inc
- Amtixbio Co Ltd
Buy Now : https://www.globalinsightservices.com/checkout/single_user/GIS31206
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/